Progress in Detection of Biomarker of Ovarian Cancer: Lysophosphatidic Acid

Abstract

Ovarian cancer is a serious threat to women's health, and its mortality rate is the highest in gynecological cancer. At present, there is a lack of effective and convenient early diagnosis techniques for ovarian cancer. Most of the patients with ovarian cancer are found in the middle and late stage, thus missing the best time for treatment. Therefore, the rapid, sensitive, economic and accurate detection of early ovarian cancer is of great significance. In recent years, lysophosphatidic acid (LPA) has been found to increase in serum in the early stage of ovarian cancer, but less in other diseases. Therefore, LPA is a promising and highly specific marker of ovarian cancer. To detect LPA, many detection techniques have been developed, and great progress has been made in this field. This paper summarizes the detection methods of LPA, and focuses on the important progress in this field in recent years. Finally, the challenges and prospects of LPA marker detection in real clinical application are also prospected. LPA is a highly specific marker for early-stage ovarian cancer and has great prospects for clinical applications. Quantitative detection of LPA in serum can be achieved through mass spectrometry and optical methods.